Clinical Trial Search

Primary: Fugl-Meyer Motor Assessment (FMA) - Motor Impairment Measure — 27.5; 29.8; 26.8; 31.8 units on a scale — p=0.18

Primary: Change in Box and Block Test (BBT) Score at 6 Months Post-Treatment — 13.5; 12.6; 9.6 blocks

Primary: Change From Baseline in Inspiratory Capacity (IC) at Isotime — 0.0035; 0.07 liter — p=0.0087

Primary: Roland-Morris Disability Questionnaire — 9.8; 5.3; 13.3; 16.7 units on a scale

Primary: Gray Matter Volume Biomarkers of 6 Month Prognosis as Measured by Voxel Based Morphometry - Within Group Comparison — 4.18; 3.27; 3.85; 3.76 peak voxel z-score

Primary: Change in Functional Disability as Measured by the Roland Morris Disability Questionnaire — 5; 4; 7 units on a scale

Primary: Detection of Expiratory Flow Limitation — 2.6 cmH2O*s/L

Primary: Primary: Change From Baseline in Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) (0-12 Hours (h)) — 0.234; 0.122; 0.155; -0.028 Liters

Primary: Boston Prep Scale — 7.0; 7.2 units on a scale — p=.45

Primary: Evaluation of Disease Duration: Time From Diagnosis to Disease-Modifying Anti-Rheumatic Drug Treatment in Rheumatoid Arthritis — 11.7177 Months

Primary: Number of Participants With Any Adverse Event (AE) and, Serious Adverse Event (SAE) in Part A — 5; 1 Participants

Primary: Change From Baseline in Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) (0-12 Hours (h)) — 0.211; 0.117; 0.112; -0.021 Liter

Primary: Number of Patients With Serious Adverse Events — 55; 55; 50 Participants

Primary: Self-reported Intake of Fruit and Vegetables (Number of Portions Per Day); — 1.9; 6.1 Portions per day

Primary: Number of Patients With Adverse Events, Serious Adverse Events, and Death — 26; 25; 24; 139 Number of Patients